Applied DNA Sciences Files S-1 Registration Statement

TL;DR

<b>Applied DNA Sciences has filed an S-1 registration statement, signaling a potential upcoming offering of securities.</b>

AI Summary

APPLIED DNA SCIENCES INC (BNBX) filed a IPO Registration (S-1) with the SEC on April 24, 2024. Applied DNA Sciences, Inc. filed an S-1 registration statement with the SEC on April 24, 2024. The company is incorporated in Delaware and its principal executive offices are located in Stony Brook, New York. James A. Hayward, Ph.D., Sc.D. is the Chairman, Chief Executive Officer, and President. The filing indicates the proposed sale of securities will commence as soon as practicable after the registration statement becomes effective. Applied DNA Sciences is identified as a smaller reporting company and a non-accelerated filer.

Why It Matters

For investors and stakeholders tracking APPLIED DNA SCIENCES INC, this filing contains several important signals. This S-1 filing is a prerequisite for offering securities to the public, indicating the company is preparing for a capital raise or other significant financial transaction. As a smaller reporting company, the filing provides insights into its financial status and strategic intentions, which are crucial for investors evaluating potential investments.

Risk Assessment

Risk Level: medium — APPLIED DNA SCIENCES INC shows moderate risk based on this filing. The company is a smaller reporting company and a non-accelerated filer, which suggests it may have limited financial resources and operational scale compared to larger, more established entities, potentially increasing financial and operational risks.

Analyst Insight

Investors should monitor the effective date of the S-1 filing and any subsequent prospectus for details on the proposed securities offering and the company's financial projections.

Key Numbers

• 2024-04-24 — Filing Date (S-1 Registration Statement)
• 0930 — Fiscal Year End (Company fiscal year)
• 333-278890 — SEC File Number (Registration)

Key Players & Entities

• Applied DNA Sciences, Inc. (company) — Registrant
• James A. Hayward (person) — Chairman, Chief Executive Officer and President
• Delaware (jurisdiction) — State of incorporation
• Stony Brook, New York (location) — Principal executive offices
• McDermott Will & Emery LLP (company) — Copies to
• Ellenoff Grossman & Schole LLP (company) — Copies to

FAQ

Risk Factors

• Smaller Reporting Company Status [medium — financial]: The company is classified as a smaller reporting company and a non-accelerated filer, which may indicate limited financial resources and operational scale.

Industry Context

Applied DNA Sciences operates in the testing laboratories sector, focusing on providing solutions that involve DNA-based technologies. The S-1 filing is a standard document for companies planning to offer securities to the public.

Regulatory Implications

The filing is made under the Securities Act of 1933, which governs the registration of securities offered to the public in the United States. The SEC reviews these filings to ensure adequate disclosure to investors.

What Investors Should Do

1. Review the full S-1 filing for detailed financial statements and risk factors.
2. Monitor SEC filings for updates on the effectiveness of the registration statement and any subsequent prospectus.
3. Analyze the company's business strategy and market position in light of the potential securities offering.

Key Dates

• 2024-04-24: S-1 Filing — Registration statement filed with the SEC.

Year-Over-Year Comparison

This is a new S-1 filing, so there is no prior filing of this type to compare against for this specific registration event.

Key Financial Figures

• $0.001 — ] shares of our common stock, par value $0.001 per share, together with Series A warra
• $0 — d to the public in this offering, minus $0.0001, and the exercise price of each pr
• $0.0001 — e of each pre-funded warrant will equal $0.0001 per share of common stock. For each pre
• $6.60 — stock on The Nasdaq Capital Market was $6.60 per share. We have engaged Craig-Hallu
• $110,000 — t-of-pocket expenses in an amount up to $110,000, and for its closing costs in an amount

Filing Documents

• tm2412319d1_s1.htm (S-1) — 487KB
• tm2412319d1_ex23-1.htm (EX-23.1) — 3KB
• tm2412319d1_ex-filingfees.htm (EX-FILING FEES) — 26KB
• tm2412319d1_s1img01.jpg (GRAPHIC) — 20KB
• tm2412319d1_s1img02.jpg (GRAPHIC) — 29KB
• 0001104659-24-050738.txt (&nbsp;) — 584KB

Forward-Looking Statements

Forward-Looking Statements 2 Prospectus Summary 3 Summary of the Offering 11

Use of Proceeds

Use of Proceeds 16 Market Price of our Common Stock and Related Stockholder Matters 16 Capitalization 17

Description of Securities

Description of Securities 19 PLAN OF DISTRIBUTION 23 Experts 25 Legal Matters 25 Where you can find more information 26 MATERIAL CHANGES 26 Incorporation by Reference 26 ABOUT THIS PROSPECTUS The information contained in this prospectus is not complete and may be changed. You should rely only on the information provided in or incorporated by reference in this prospectus, or in a related free writing prospectus, or documents to which we otherwise refer you. We have not authorized anyone else to provide you with different information. We have not authorized any dealer, agent or other person to give any information or to make any representation other than those contained or incorporated by reference in this prospectus or any related free writing prospectus. You must not rely upon any information or representation not contained or incorporated by reference in this prospectus or any related free writing prospectus. This prospectus and any related free writing prospectus, if any, do not constitute an offer to sell or the solicitation of an offer to buy any securities other than the registered securities to which they relate, nor do this prospectus and any related free writing prospectus, if any, constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such jurisdiction. You should not assume that the information contained in this prospectus and any related free writing prospectus, if any, is accurate on any date subsequent to the date set forth on the front of such document or that any information we have incorporated by reference is correct on any date subsequent to the date of the document incorporated by reference, even though this prospectus and any related free writing prospectus is delivered or securities are sold on a later date. We have not done anything that would permit this offering or possession or distribution of this pr

Forward-looking statements

Forward-looking statements may include our plans and objectives for future operations, including plans and objectives relating to our products and our future economic performance, projections, business strategy and timing and likelihood of success. Assumptions relating to the foregoing involve judgments with respect to, among other things, future economic, competitive and market conditions, future business decisions, demand for our products and services, and the time and money required to successfully complete development and commercialization of our technologies, all of which are difficult or impossible to predict accurately and many of which are beyond our control. Any of the assumptions underlying the forward-looking statements contained in this prospectus could prove inaccurate and, therefore, we cannot assure you that any of the results or events contemplated in any of such forward-looking statements will be realized. Based on the significant uncertainties inherent in these forward-looking statements, the inclusion of any such statement should not be regarded as a representation or as a guarantee by us that our objectives or plans will be achieved, and we caution you against relying on any of the forward looking-statements contained herein. PROSPECTUS SUMMARY This summary highlights certain information about us, this offering and information appearing elsewhere in this prospectus and in the documents we incorporate by reference in this prospectus. This summary is not complete and does not contain all of the information that you should consider before investing in our securities. After you carefully read this summary, to fully understand our Company and this offering and its consequences to you, you should read this entire prospectus and any related free writing prospectus authorized by us, including the information referred to under the heading "Risk Factors" in this prospectus beginning on page 12, and any related free writing prospectus, as well as the o

View Full Filing

View this S-1 filing on SEC EDGAR